Stocks Health care PFE
NYSE · Health carePfizer Inc (PFE)
Pfizer Inc brought in $63.7B of revenue over the twelve months to June 28, 2026, down 0.2% from a year earlier. Net income was $4.3B, a net margin of 6.8%. Operating cash flow minus capital spending left $9.1B of free cash flow in fiscal 2025. At June 28, 2026 it held $976M in cash against $63.1B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.
Key facts about Pfizer Inc
- Net worth
- Pfizer Inc has a market value (market cap) of $161.9B at the latest share price, and shareholders' equity of $85.2B on its balance sheet at June 28, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $62.6B (-1.6% year on year), with net income of $7.8B. Over the 12 months to June 28, 2026: revenue $63.7B, net income $4.3B.
- Cash flow
- In fiscal 2025 operations brought in $11.7B of cash; after $2.6B of capital spending, free cash flow was $9.1B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 4, 2026 and covers the period to June 28, 2026. Open on SEC EDGAR
- Next earnings report
- Pfizer Inc's next report is expected around November 3, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- Pfizer Inc declared dividends of $1.72 per share in fiscal 2025, a yield of 6.06% at the current price.
What Pfizer Inc does
Pfizer discovers, develops, manufactures, and sells prescription medicines and vaccines. Its products treat conditions in oncology, cardiology, immunology, and infectious diseases. Customers include healthcare providers, hospitals, pharmacies, and government agencies worldwide. Its shares trade on NYSE under the ticker PFE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $62.6B | $7.8B | $1.36 | $9.1B |
| 2024 | $63.6B | $8B | $1.41 | $9.8B |
| 2023 | $59.6B | $2.1B | $0.37 | $4.8B |
| 2022 | $101.2B | $31.4B | $5.47 | $26B |
| 2021 | $81.3B | $22B | $3.85 | $29.9B |
| 2020 | $41.7B | $9.2B | $1.63 | $12.2B |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where PFE ranks in Health care
Dividends
Pfizer Inc declared $1.72 per share in fiscal 2025. At the current price that is a yield of 6.06%. It paid out $9.8B in cash dividends, 126% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $1.72 | $9.8B | 126% |
| 2024 | $1.69 | $9.5B | 118% |
| 2023 | $1.65 | $9.2B | 436% |
| 2022 | $1.61 | $9B | 29% |
| 2021 | $1.57 | $8.7B | 40% |
| 2020 | $1.53 | $8.4B | 92% |
Latest SEC filings
What Pfizer Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 31, 2026Form N-PX filing N-PX
- August 13, 2026Form 13F-HR filing 13F-HR
- August 4, 2026Quarterly report 10-Q · period to June 28, 2026Revenue rose 2.6% to $15B versus the same quarter last year; diluted EPS -$0.04 versus $0.51.
- August 4, 2026
- June 18, 2026
- June 18, 2026
- June 16, 2026
- June 16, 2026
- May 12, 2026Passive stake changed SCHEDULE 13G/A
- May 12, 2026Form 13F-HR filing 13F-HR
What is PFE worth? A DCF from its reported cash flow
Insider trades
What the people running Pfizer Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $3M and sold $83.3K worth of shares in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 12, 2026 | Bourla AlbertChairman & CEO, Director | Bought | 38,000 | $1M |
| August 5, 2026 | Damico Jennifer B.SVP & Controller | Sold | 3,278 | $83.3K |
| August 5, 2026 | Buckley Mortimer JDirector | Bought | 37,632 | $960.4K |
| August 5, 2026 | Blaylock Ronald EDirector | Bought | 39,231 | $998.8K |
| June 9, 2026 | Damico Jennifer B.SVP & Controller | Sold | 2,000 | $51.4K |
| March 4, 2026 | Damico Jennifer B.SVP & Controller | Shares withheld for tax | 826 | $22K |
| March 3, 2026 | Damico Jennifer B.SVP & Controller | Received as pay | 16,311 | - |
| March 3, 2026 | Damico Jennifer B.SVP & Controller | Received as pay | 5,408 | - |
Who owns PFE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Pfizer Inc. (“Pfizer”)13D, may seek influence | 13.14% | October 25, 2023 |
| Vanguard Capital Management13G, passive | 7.51% | May 1, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 2,823 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 529,670,433 | +31,412,883 |
| Vanguard Capital Management LLC | 372,149,852 | +2,719,840 |
| State Street Corp | 307,090,897 | +5,501,032 |
| Geode Capital Management, LLC | 135,275,782 | +1,714,040 |
| Vanguard Portfolio Management LLC | 119,235,030 | +2,500,335 |
| Fisher Asset Management, LLC | 109,067,291 | +4,102,864 |
| Morgan Stanley | 96,345,452 | +3,660,082 |
| Norges Bank | 61,505,586 | new |
| Northern Trust Corp | 59,084,573 | -2,941,979 |
| Bank of New York Mellon Corp | 57,879,546 | +3,999,646 |
| Massachusetts Financial Services Co | 56,551,011 | -360,819 |
| State Farm Mutual Automobile Insurance Co | 54,508,560 | 0 |
| Goldman Sachs Group Inc | 52,991,850 | +5,886,294 |
| Charles Schwab Investment Management Inc | 52,548,228 | +656,592 |
| Bank of America Corp | 43,588,109 | -2,957,370 |
| Legal & General Group Plc | 43,233,122 | -272,441 |
| Dimensional Fund Advisors LP | 38,060,345 | +1,637,546 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 36,157,306 | +1,634,374 |
| Amundi | 33,533,616 | -7,291,854 |
| Royal Bank of Canada | 32,814,260 | -1,341,580 |
Insiders
9 insiders reported holding 1,035,340 shares in total, about $29.4M at the last price.
| Holder | Shares |
|---|---|
| Bourla AlbertChairman & CEO, Director | 429,173 |
| Lankler Douglas MExecutive Vice President | 163,177 |
| Boshoff ChristoffelPresident, R&D | 161,379 |
| McDermott MichaelExecutive Vice President | 74,308 |
| Blaylock Ronald EDirector | 66,938 |
| Fonseca LidiaExecutive Vice President | 46,455 |
| Buckley Mortimer JDirector | 37,632 |
| Damico Jennifer B.SVP & Controller | 28,611 |
| Sahni PayalExecutive Vice President | 27,667 |
Questions about PFE
What does Pfizer Inc do?
Pfizer discovers, develops, manufactures, and sells prescription medicines and vaccines. Its products treat conditions in oncology, cardiology, immunology, and infectious diseases. Customers include healthcare providers, hospitals, pharmacies, and government agencies worldwide. Its shares trade on NYSE under the ticker PFE.
What is Pfizer Inc's net worth?
Pfizer Inc has a market value (market cap) of $161.9B at the latest share price, and shareholders' equity of $85.2B on its balance sheet at June 28, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Pfizer Inc profitable?
Yes. Over the twelve months to June 28, 2026 it reported net income of $4.3B on revenue of $63.7B, a net margin of 6.8%.
How much revenue does Pfizer Inc make?
Over the twelve months to June 28, 2026 Pfizer Inc reported revenue of $63.7B. That is 0.2% less than a year earlier.
When did Pfizer Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 28, 2026. Its newest filing of any kind is the insider trade from October 1, 2026.
When is Pfizer Inc's next earnings report?
Pfizer Inc's next report is expected around November 3, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Does Pfizer Inc pay a dividend?
Yes. Pfizer Inc declared dividends of $1.72 per share in fiscal 2025, a yield of 6.06% at the current price.
Similar companies
Compare PFE with
Follow PFE
Get an email when Pfizer Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Pfizer Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.